|
Name |
Carvotanacetone
|
| Molecular Formula | C10H16O | |
| IUPAC Name* |
(5S)-2-methyl-5-propan-2-ylcyclohex-2-en-1-one
|
|
| SMILES |
CC1=CC[C@@H](CC1=O)C(C)C
|
|
| InChI |
InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,7,9H,5-6H2,1-3H3/t9-/m0/s1
|
|
| InChIKey |
WPGPCDVQHXOMQP-VIFPVBQESA-N
|
|
| Synonyms |
Carvotanacetone; 2-Cyclohexen-1-one, 2-methyl-5-(1-methylethyl)-, (S)-; (5S)-2-methyl-5-propan-2-ylcyclohex-2-en-1-one; p-Menth-6-en-2-one, (S)-(+)-; 499-71-8; (+)-Carvotanacetone; Carvotanacetone, (+)-; SCHEMBL11902533; CHEBI:171922; (A+/-)-p-menth-6-en-2-one; ZINC12153091; (5S)-2-Methyl-5alpha-isopropyl-2-cyclohexene-1-one
|
|
| CAS | NA | |
| PubChem CID | 6432475 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 152.23 | ALogp: | 2.5 |
| HBD: | 0 | HBA: | 1 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 17.1 | Aromatic Rings: | 1 |
| Heavy Atoms: | 11 | QED Weighted: | 0.563 |
| Caco-2 Permeability: | -4.375 | MDCK Permeability: | 0.00002650 |
| Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.004 |
| Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.795 |
| 30% Bioavailability (F30%): | 0.496 |
| Blood-Brain-Barrier Penetration (BBB): | 0.978 | Plasma Protein Binding (PPB): | 65.02% |
| Volume Distribution (VD): | 0.829 | Fu: | 45.00% |
| CYP1A2-inhibitor: | 0.373 | CYP1A2-substrate: | 0.419 |
| CYP2C19-inhibitor: | 0.322 | CYP2C19-substrate: | 0.812 |
| CYP2C9-inhibitor: | 0.169 | CYP2C9-substrate: | 0.438 |
| CYP2D6-inhibitor: | 0.032 | CYP2D6-substrate: | 0.508 |
| CYP3A4-inhibitor: | 0.072 | CYP3A4-substrate: | 0.321 |
| Clearance (CL): | 13.328 | Half-life (T1/2): | 0.656 |
| hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.296 |
| Drug-inuced Liver Injury (DILI): | 0.046 | AMES Toxicity: | 0.01 |
| Rat Oral Acute Toxicity: | 0.034 | Maximum Recommended Daily Dose: | 0.321 |
| Skin Sensitization: | 0.951 | Carcinogencity: | 0.769 |
| Eye Corrosion: | 0.961 | Eye Irritation: | 0.988 |
| Respiratory Toxicity: | 0.735 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000194 | ![]() |
0.487 | D06GIP | ![]() |
0.208 | ||
| ENC001903 | ![]() |
0.404 | D0H1QY | ![]() |
0.208 | ||
| ENC000165 | ![]() |
0.381 | D04CSZ | ![]() |
0.208 | ||
| ENC005928 | ![]() |
0.370 | D09PJX | ![]() |
0.192 | ||
| ENC000196 | ![]() |
0.333 | D06IXT | ![]() |
0.190 | ||
| ENC003371 | ![]() |
0.326 | D0K7LU | ![]() |
0.182 | ||
| ENC001823 | ![]() |
0.321 | D06XWB | ![]() |
0.179 | ||
| ENC003093 | ![]() |
0.309 | D0A2AJ | ![]() |
0.179 | ||
| ENC000520 | ![]() |
0.302 | D01PJR | ![]() |
0.179 | ||
| ENC000197 | ![]() |
0.302 | D06PSS | ![]() |
0.177 | ||